23:07 , Aug 15, 2019 |  BC Innovations  |  Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

Adaptive’s float to more than $5 billion after its June IPO is largely based on its ambition to compete with the likes of Grail and Guardant in early diagnosis of cancer and other diseases by...
20:22 , May 1, 2019 |  BC Extra  |  Preclinical News

May 1 Preclinical Quick Takes: MD Anderson, Sana, Sigilon

MD Anderson findings could make radiation possible for pancreatic cancer  Researchers at University of Texas MD Anderson Cancer Center reported findings suggesting that HIF-PH inhibition could help prevent radiation-induced GI injury, the main factor that...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
23:13 , Mar 26, 2019 |  BC Extra  |  Company News

Sana adds hypoimmunogenic stem cell tech from Harvard to its tool kit

Building out its portfolio of cell and gene therapy tools, Sana licensed technology from Harvard University comprising methods to create stem cells that avoid triggering immune rejection when transplanted. The hypoimmunogenic stem cells are derived...
02:34 , Feb 26, 2019 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method for making iPS cells hypoimmunogenic could be used to generate allogeneic cell grafts for transplant therapies. The method involves two to three steps: simultaneous or sequential CRISPR-Cas9 (CRISPR-associated protein 9)-mediated...
22:37 , Feb 20, 2019 |  BC Extra  |  Preclinical News

Engineering allogeneic iPS cells to avoid transplant rejection

UCSF researchers have made headway toward developing universal allogeneic iPS cell therapies by identifying a dual mechanism that prevented immune rejection in mice. Adult stem cells have shown limited efficacy as a regenerative strategy for...
17:40 , Dec 11, 2018 |  BC Innovations  |  Translation in Brief

Diseased oligodendrocytes

A Karolinska Institute team has identified subsets of oligodendrocyte lineage cells that may trigger T cell immunity in multiple sclerosis and proposed the cells as new disease targets. The findings suggest the myelin-producing cells are...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
16:43 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with alpha fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) in a...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...